Biofrontera AG

Industry

  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Biotechnology

Other Names/Subsidiaries

  • Biofrontera Bioscience GmbH
  • Biofrontera Development GmbH
  • Biofrontera Pharma GmbH
  • Cutanea Life Sciences, Inc.
See more in Biomedtracker

Latest on Biofrontera AG

Scrip

Almirall Aims To Disrupt Actinic Keratosis Space With Klisyri

 
• By Kevin Grogan

Klisyri has got off to a good start in the US and Almirall SA is now getting ready for launch in Europe, having received a positive opinion from the Committee for Medicinal Products for Human Use (C

Scrip

Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

 
• By Ian Haydock, Joseph Haas, Vibha Ravi, and Jung Won Shin

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Appili Gains Rights To FUJIF

Scrip

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

 
• By Joseph Haas, Jung Won Shin, Brian Yang, and Ian Haydock

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Strategic Transactions . Celltrion Teams With iProgen

Scrip

Good Prospects For Athenex/Almirall Following PhIII Actinic Keratosis Results

 
• By Eleanor Malone

Athenex Inc. and its partner Almirall SA have achieved the primary endpoint of 100% clearance of actinic keratosis lesions at Day 57 in two Phase III trials of the topical ointment KX2-391. Data de